Abstract: The invention is to develop a protecting group that does not solidify or insolubilize a compound in which a functional group has been protected, and facilitates separation and purification after a reaction.

Abstract: Continuous processes for making ethylene glycol form aldohexose-yielding carbohydrates are disclosed which enhance the selectivity to ethylene glycol.

Abstract: A pure composition comprises a monoalkyltin trialkoxide compound represented by the chemical formula RSn(OR?)3 or a monoalkyl tin triamide compound represented by the chemical formula RSn(NR?2)3 and no more than 4 mole % dialkyltin compounds relative to the total tin amount, where R is a hydrocarbyl group with 1-31 carbon atoms, and wherein R? is a hydrocarbyl group with 1-10 carbon atoms. Methods are described for the formation of the pure compositions. A solid composition comprises a monoalkyl triamido tin compound represented by the chemical formula RSn—(NR?COR?)3, where R is a hydrocarbyl group with 1-31 carbon atoms, and where R? and R? are independently a hydrocarbyl group with 1-10 carbon atoms. The compositions are suitable for the formation of resist compositions suitable for EUV patterning in which the compositions have a high EUV absorption.

Abstract: An object of the present invention is to provide a novel complex having at least two carbon-carbon double bonds and/or carbon-carbon triple bonds. The present invention provides a complex represented by a structural formula (2): [In the structural formula (2), M1 to M4 are identical to or different from each other and represent a metal atom, R1 to R6 are identical to or different from each other and represent a hydrogen atom, an alkyl group having 1 to 24 carbon atoms, an alkenyl group having 2 to 18 carbon atoms or an alkynyl group having 2 to 18 carbon atoms, at least two of R1 to R6 are the alkenyl group having 2 to 18 carbon atoms or the alkynyl group having 2 to 18 carbon atoms, and at least one of R1 to R6 is the alkyl group having 6 to 24 carbon atoms].

Abstract: The present invention relates to a continuous flow hydrogenation process and process apparatus.

Abstract: Methods of preparing a fenfluramine active pharmaceutical ingredient are provided. Aspects of the method include (a) hydrolyzing a 2-(3-(trifluoromethyl)phenyl)acetonitrile composition to produce a 2-(3-(trifluoromethyl)phenyl)acetic acid composition; (b) reacting the 2-(3-(trifluoromethyl)phenyl)acetic acid composition with acetic anhydride and a catalyst to produce a 1-(3-(trifluoromethyl)phenyl)propan-2-one composition; and (c) reductively aminating the 1-(3-(trifluoromethyl)phenyl)propan-2-one composition with ethylamine using a borohydride reducing agent to produce a fenfluramine composition. Also provided are compositions and pharmaceutical ingredients prepared according to the subject methods including a pharmaceutically acceptable salt of fenfluramine and having less than 0.2% by weight in total of trifluoromethyl regioisomers.

Abstract: Provided herein is a two-component photosensitizer, which demonstrated robust and selective killing effects for transfected HEK cells and affibody targeted A431 cancer cells when exposed to near infrared light excitation. Free MG2I is a pure and stable fluorogen; it is easy to synthesize and modify, and has no toxicity to cells. Unlike conventional photosensitizers, the dye and FAP itself has no photosensitizing effect until they are bound. Also unlike other activation methods, the activation step is achieved by adding the fluorogen, not the presence of the targeted molecule, requiring an ‘active’ activation instead of a ‘passive’ activation. This method offers the ability to locally switch-on and selective generation of singlet oxygen at the target site and can be used for a wide variety of molecular targets.

Abstract: The present invention relates to a water-stable Titanium-based metal-organic framework (MOF) material having a high degree of condensation, i.e. an oxo to Ti ratio (or oxo to metal ratio, in the case of doped Ti-based MOFs) >1.0; a process of preparing same and uses thereof, particularly for heterogeneously catalyzed chemical reactions, for gas storage/separation/purification, for information storage, laser printing or as an oxygen indicator, or as proton conductive material (fuel cells), optoelectronic material (photovoltaic cells including Grätzel cells), as a matrix for encapsulating active principles (medicaments, cosmetics), or else as sensing material.

Abstract: This invention relates to a catalyst composition for a producing process of an unsaturated carboxylic acid salt and its derivatives from carbon dioxide and olefin, wherein the catalyst composition in the present invention has been proved to be effective in catalyzing the carboxylation of carbon dioxide and olefin, wherein said catalyst composition comprises: a) a palladium metal complex as shown in structure (I); wherein, R1, R2, R3, and R4 independently represents a group selected from hydrogen atom, halogen atom, alkyl group, alkyl halide group, alkoxy group, amine group, optionally from alkenyl group, alkynyl group, phenyl group, benzyl group, or cylic hydrocarbon group comprising hetero atom; R5 represents group selected from alkyl group or phenyl group; b) a ligand selected from organophosphorus compound; c) a base selected from sodium tert-butoxide, sodium isopropoxide, sodium 2,6-dimethylphenolate, sodium 2,6-difluorophenolate, sodium 2-methylphenolate, or sodium 2-fluorophenol); and d

Abstract: The present invention specifically relates to novel salt and crystalline form of haloacetic acid and its process of preparation. The invention more particularly relates to novel crystalline form dichloroacetate tromethamine salt and its process of preparation. The present invention more specifically relates to the dichloroacetate tromethamine salt, its process and its use for the treatment of various diseases and/or disorders.

Abstract: The disclosure provides a method for synthesizing free base forms of (2R,6R)-hydroxynorketamine (HNK) and (2S,6S)-hydroxynorketamine. In an embodiment synthesis of (2R,6R)-hydroxynorketamine (HNK) includes preparation of (R)-norketamine via chiral resolution from racemic norketamine via a chiral resolution with L-pyroglutamic acid. The disclosure also provided crystal forms of the corresponding (2R,6R)-hydroxynorketamine (HNK) and (2S,6S)-hydroxynorketamine hydrochloride salts.

Abstract: The invention describes hydrosoluble iron (III) oxyhydroxide complexes prepared from different sources of iron, amino acids and carboxylic acids. The iron (III) complexes have no undesirable residual taste and can be used as supplementation forms for the prevention or treatment of iron deficiency anemia in humans or animals and pharmaceutical or food compositions containing them.

Abstract: A lanthanum compound, a method of synthesizing a thin film, and a method of manufacturing an integrated circuit device, the compound being represented by Formula 1 below, wherein, in Formula 1, R1 is a hydrogen atom or a C1-C4 linear or branched alkyl group, R2 and R3 are each independently a hydrogen atom or a C1-C5 linear or branched alkyl group, at least one of R2 and R3 being a C3-C5 branched alkyl group, and R4 is a hydrogen atom or a C1-C4 linear or branched alkyl group.

Abstract: The present invention relates to: a novel transition metal compound; a preparation method therefor; a composition for depositing a transition metal-containing thin film, containing the same; a transition metal-containing thin film using the composition for depositing a transition metal-containing thin film; and a method for preparing a transition metal-containing thin film. The transition metal compound of the present invention has high thermal stability, high volatility, and high storage stability, and thus a transition metal-containing thin film having high-density and high-purity can be easily prepared by using the same as a precursor.

Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L1, n and p are defined herein. The compounds of formula (X) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

Abstract: The present invention provides a process for the preparation of N-phenoxyisopropyl ethanolamine of Formula (II) and its conversion to Phenoxybenzamine of Formula (I) or pharmaceutically acceptable salts thereof.

Abstract: A method for manufacturing an amino group-containing organosilicon compound of the following formula (1): wherein each R1 independently represents an alkyl group having 1 to 10 carbon atoms, etc., each of R2 and R3 represents a functional group of the following formula (4), etc., m represents an integer of 1 to 3, and n represents an integer of 1 to 12, wherein an asterisk * represents a bond with an adjacent atom, p represents an integer of 1 to 12, and q represents an integer of 1 to 10, the method comprising: (A) reacting an amine compound of the following formula (2): wherein R2 and R3 mean the same as above with a halogen group-containing organosilicon compound of the following formula (3): wherein X represents a chlorine atom, etc., and R1 and n mean the same as above; (B) removing an amine hydrohalide produced in the step (A), by liquid-liquid separation; and (C) neutralizing an organic layer obtained in the step (B), using a base which amounts 0.1 to 0.

Abstract: A method of separating a metal organic framework (MOF) from a solution and associated apparatus. The method comprises: providing a MOF containing solution; contacting the MOF containing solution with an acoustic reflector surface such that, any high frequency ultrasound applied within the MOF containing solution reflects off the acoustic reflector surface; and applying a high frequency ultrasound of at least 20 kHz to the MOF containing solution. The MOF material is substantially separated from solution as aggregated sediment that settles out of solution.

Abstract: Provided is a desulfurizer for removing a sulfur compound contained in a fluid, comprising a desulfurization agent for removing the sulfur compound from the fluid and a housing which contains the desulfurization agent and the inside of which the fluid flows through. The desulfurization agent includes a metal organic framework. The metal organic framework has copper ions and organic ligands. The organic ligands include 1,3,5-benzenetricarboxylic acid and 1,3-benzenedicarboxylic acid.

Abstract: The present invention relates to a method for manufacturing a catalyst for synthesizing a fatty acid methyl or ethyl ester and a method for manufacturing a fatty acid methyl or ethyl ester using the catalyst. It provides a method for manufacturing a solid catalyst by mixing the oxides of manganese as active catalytic material and the soda lime glass as carrier wherein the content of the oxides of manganese is in the range of 0.1 w % to 70 w %, molding the mixture to spherical or cylindrical shape and sintering the molded catalyst. It also provides a method for manufacturing fatty acid methyl or ethyl ester with high purity by reacting fatty acid or a mixture of oil and fatty acid with methanol or ethanol by placing the solid catalyst in the reactor.